← All trials
NCT05946876
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2023
- Primary completion
- Feb 18, 2024
- Completion date
- Jun 16, 2024
- First posted
- Jul 14, 2023
- Last posted
- Jul 24, 2023
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Infinity Pharmaceuticals, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.